UK launches £50m Life Sciences Transformational R&D Investment Fund (TRIF) Pilot

Mechanism

TRIF is a competitive capital-grant pilot administered jointly by DSIT and the Office for Life Sciences, aimed at anchoring large-scale ("transformational") life-sciences R&D investment in the UK. The GBP 100m minimum total-project-cost threshold and 10-20% grant-intensity band mean the fund is designed to top up a small number of large, already-committed private capital projects rather than seed early-stage R&D — a targeted co-investment instrument, not a broad sectoral subsidy. It sits alongside the separate Life Sciences Innovative Manufacturing Fund (LSIMF), part of the UK's wider Life Sciences Sector Plan.

Downstream implications

• Modest scale (GBP 50m) relative to comparable US/EU life-sciences and

biomanufacturing incentive programmes; primarily a signalling and co-investment tool to keep large pharma/biotech capex projects onshore.

• Rolling EOI process to 2028 means the fund's practical effect will show up

gradually as individual project awards are announced, not at launch.

• No targeted countries or trade-restrictive mechanism; classified here as a

domestic industrial-policy subsidy within the broader Western industrial-policy stack.

Open questions

• No named recipients yet — first EOI/award announcements will indicate

which large life-sciences capex projects (and by extension, which multinationals) the fund is actually supporting.

• Unclear whether TRIF will be topped up beyond the initial GBP 50m if

demand from qualifying (>GBP 100m) projects exceeds pilot capacity.